References
- EFPIA. Pharmaceutical R&D expenditure in Europe, USA and Japan (million of national currency units*), 1995-2015. 2016 Dec 31 [cited 2017 Dec 12]. Available from: https://www.efpia.eu/publications/data-center/the-pharma-industry-in-figures-rd/pharmaceutical-rd-expenditure-in-europe-usa-and-japan/
- Dierks R, Bruyère O, Reginster JY, et al. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Rev Pharmacoecon Outcomes Res. 2016 Oct 05; sec. A;1:1–6.
- Kurmann Partners. Cooling down – or the calm before the storm. 2017 Jan 31 [cited 2017 Aug 11]. Available from: http://www.kurmannpartners.com/fileadmin/user_upload/import2015/MR-Pharma_Biotech/KP_-_The_year_2016_in_review.pdf
- Novartis. Kenya first country to launch ‘Novartis Access’, expanding affordable treatment options against chronic diseases. 2015 Oct 15 [cited 2017 Dec 12]. Available from: https://www.novartis.com/news/media-releases/kenya-first-country-launch-novartis-access-expanding-affordable-treatment
- EvaluatePharma. World preview 2017, outlook to 2022. 2017 June 30 [cited 2017 Aug 20]. Available from: http://info.evaluategroup.com/rs/607-YGS-364/images/WP17.pdf
- KPMG. 2017 M&A predictor. 2017 Jan 31 [cited 2017 Aug 05]. Available from: https://assets.kpmg.com/content/dam/kpmg/xx/pdf/2017/04/global-manda-deals.pdf
- Moody’s. Global pharma industry outlook change to stable reflect lower growth expectations. 2016 Mar 03 [cited 2017 Aug 05]. Available from: https://www.moodys.com/research/Moodys-Global-pharma-industry-outlook-change-to-stable-reflects-lower–PR_345012
- KPMG. 2017 M&A predictor. 2017 July 31 [cited 2017 Aug 05]. Available from: https://assets.kpmg.com/content/dam/kpmg/xx/pdf/2017/04/global-manda-deals.pdf
- Investopedia. Valuation. 2017 Jan 31 [cited 2017 Aug 05]. Available from: http://www.investopedia.com/terms/v/valuation.asp
- Bloomberg. Bloomberg professional. 2017 [cited 2017 Aug 25]. Available from: Subscription Service
- Kurmann Partners. Global M&A report pharma/biotech 2016. 2016 Jan 31 [cited 2017 Aug 11]. Available from: http://www.kurmannpartners.com/fileadmin/user_upload/import2015/MR-Pharma_Biotech/KP_-_The_year_2016_in_review.pdf
- Christy G. Free cash flow: seeing through the accounting fog machine to find great stocks. 2009 Feb 09. sec. A. pp.50–76
- California Biomedical Research Association. Factsheets: CBRA drug development 2016 July 31 [cited 2017 Aug 01]. Available from: https://www.ca-biomed.org/pdf/media-kit/fact-sheets/CBRADrugDevelop.pdf
- Bloomberg. Bloomberg professional. 2017 [cited 2017 Oct 03]. Available from: Subscription Service
- Pfizer. Pfizer to acquire medivation. 2016 Aug 21 [cited 2017 Aug 18]. Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_medivation https://www.medivation.com/
- CNBC. Medivation shares leap on Pfizer’s USD 14 billion offer. 2016 Aug 22 [cited 2017 Aug 18]. Available from: https://www.cnbc.com/2016/08/22/medivation-shares-surge-on-14-billion-dollar-offer-from-pfizer.html
- Pfizer. Pfizer completes acquisition of medivation. 2016 Sep 28 [cited 2017 Aug 18]. Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_medivation
- Astellas. FDA accepts for review supplemental new drug application for XTANDI® (enzalutamide) capsules in metastatic castration-resistant prostate cancer with data from head-to-head studies of enzalutamide versus bicalutamide. 2016 Feb 28 [cited 2017 Aug 20]. Available from: http://newsroom.astellas.us/2016-02-22-FDA-Accepts-For-Review-Supplemental-New-Drug-Application-for-XTANDI-enzalutamide-Capsules-in-Metastatic-Castration-resistant-Prostate-Cancer-with-Data-from-Head-to-Head-Studies-of-Enzalutamide-Versus-Bicalutamide
- World Health Organization. Cancer key facts. 2017 Feb 28 [cited 2017 Aug 20]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
- Crawford ED. Moving forward in castration-resistant prostate cancer: the TERRAIN and STRIVE studies. 2016 May 10 [cited 2017 Aug 20]. Available from: http://www.ascopost.com/issues/may-10-2016/moving-forward-in-castrate-resistant-prostate-cancer-the-terrain-and-strive-studies/
- Grover N. Mylan to buy Swedish drugmaker Meda in $7.2 billion deal. 2016 Feb 11 [cited 2017 Sep 02]. Available from: http://www.reuters.com/article/us-meda-m-a-mylan-nl-idUSKCN0VJ2IK
- Nordenstam S, Shanley M Swedish drugmaker Meda spurns Mylan takeover approach. 2014 Apr 04 [cited 2017 Sep 02]. Available from: http://www.reuters.com/article/us-meda-mylan-idUSBREA3310020140404
- Wieczner J Fat pharma: Pfizer-Hospira and the top 10 overpriced drug deals ever. 2015 Feb 06 [cited 2017 Sep 02]. Available from: http://fortune.com/2015/02/06/pfizer-hospira-top-10-fattest-pharma-deals/
- Bloomberg. Bloomberg professional. 2017 [cited 2017 Sep 02]. Available from: Subscription Service
- Staff R. AstraZeneca sells aging beta-blocker to Recordati for $300 million. 2017 May 22 [cited 2017 Sep 02]. Available from: http://www.reuters.com/article/us-astrazeneca-recordati-idUSKBN18I0OO
- Ogilvie J. Management accounting financial strategy. CIMA official learning systems. 2008 Jul 08;9:271–272.
- Palmer E. Novartis follows brand offloading trend, selling drugs in Japan to Sun. 2016 May 30 [cited 2017 Sep 02]. Available from: http://www.fiercepharma.com/pharma/novartis-follows-brand-offloading-trend-selling-drugs-japan-to-sun
- White C. Strategic management, Palgrave Macmillan. 2004 Feb 16. sec. A. 779–781
- Shipway I. Modern portfolio theory. Oxford Academic. 2009 Apr 01;15(2):66–70.
- Jansen S. Mergers & Acquistions – unternehmensakquisitionen und –kooperationen [Translated: Corporate Acquisitions and Co-Operation. A Strategic, Organizational and Capital Market Theory Introduction]. Eine Strategische, Organisatorische Und Kapitalmarkttheoretische Einführung. 2016 Feb 02;6:30–70.
- Jensen M. The agency cost of free cash flow, corporate finance and takeovers. American Economic Review. 1986 May 05;76(2):323–329.
- Legal Information Institute. 26 U.S. Code § 1248 - Gain from certain sales or exchanges of stock in certain foreign corporations.2017 Sep 15 [cited 2017 Sep 15]. Available from: https://www.law.cornell.edu/uscode/text/26/1248
- Kollewe J, Treanor J. Pfizer formally abandons $160bn Allergan deal after US tax inversion clampdown. 2016 Apr 06 [cited 2017 Sep 18]. Available from: https://www.theguardian.com/business/2016/apr/05/pfizer-allergan-merger-tax-avoidance-rules
- Treasury. Fact sheet: treasury actions to rein in corporate tax inversions. 2014 Sep 22 [cited 2017 Sep 18]. Available from: https://www.treasury.gov/press-center/press-releases/Pages/jl2645.aspx
- Gelles D, Bray C Drug firms make haste to elude tax. 2014 Jul 14 [cited 2017 Sep 18]. Available from: https://dealbook.nytimes.com/2014/07/14/shire-and-abbvie-in-talks-over-53-billion-pharmaceutical-merger/?mcubz=1
- Institute of Taxation and Economic Policy. Fortune 500 companies hold a record $2.6 trillion offshore. 2017 Mar 28 [cited 2017 Sep 20]. Available from: https://itep.org/wp-content/uploads/pre0327.pdf
- Grahame RD. Curious case of corporate tax avoidance: is it socially irresponsible? 2014 Sep. 15. sec A., 173–184.
- Cox J Wall Street week ahead: tax reform, tech and the latest on the housing market. 2017 Sep 25 [cited 2017 Sep 25]. Available from: https://www.cnbc.com/2017/09/24/wall-street-week-ahead-tax-reform-tech-and-the-latest-on-the-housing-market.html
- Bloomberg. What we know about corporate winners and losers in US Tax Bill. 2017 Dec 4. [cited 2017 Dec 6]. Available from: https://www.bloomberg.com/news/articles/2017-12-04/what-we-know-about-corporate-winners-and-losers-in-u-s-tax-bill
- US. Food and Drug Administration. CDER 2016 actions and 2017 priorities. 2016 Dec 31 [cited 2017 Oct 19]. Available from: https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM533192.pdf
- Capron L. Build, borrow or buy: solving the growth dilemma. 2012 Aug 12, 22–27